Home › All Companies › CGTX

COGNITION THERAPEUTICS INC (CGTX)

AI-Powered SEC Filing Analysis

Quarterly Report Filed: 2026-05-08

Key Insights

  • Company maintains active at-the-market (ATM) offering programs established in 2025, providing flexibility for capital raises but potentially indicating ongoing funding needs and equity dilution concerns for existing shareholders.
  • Multiple equity financing activities documented including registered direct offerings and placement agent warrants in August 2025, suggesting the company is actively managing its balance sheet through various capital markets instruments.
  • Share-based compensation programs remain active with restricted stock units (RSUs) and stock options outstanding, indicating continued use of equity incentives for employee retention despite being a clinical-stage biotech company.
  • Insurance premium financing arrangements are in place, suggesting the company is managing cash flow carefully and utilizing third-party financing for operational expenses such as insurance premiums.
Sentiment: Neutral Significance: 5/10
View Original Filing →
Current Report Filed: 2026-05-07

Key Insights

  • Cognition Therapeutics announced Q1 2026 financial results on May 7, 2026, with detailed results furnished via press release in Exhibit 99.1, though the specific financial metrics are not visible in the 8-K filing itself.
  • The company is an emerging growth company on Nasdaq (CGTX) and has elected to use the standard transition period for new accounting standards, indicating compliance with standard regulatory frameworks.
  • Lisa Ricciardi serves as President and CEO, signing the 8-K filing, confirming stable leadership at the time of earnings announcement.
Sentiment: Neutral Significance: 3/10
View Original Filing →
Insider Trading Filed: 2026-05-04

Key Insights

  • CFO John Brendan Doyle executed a tax withholding transaction on 05/01/2026, disposing of 8,567 shares at $1.28 per share to cover RSU vesting obligations, indicating ongoing equity compensation activity.
  • Following this transaction, Doyle maintains direct beneficial ownership of 618,942 shares, demonstrating substantial personal investment and confidence in the company despite the share disposition being tax-driven rather than voluntary selling.
  • The transaction represents a routine tax withholding event rather than discretionary insider selling, which has minimal predictive value for future stock performance or insider sentiment about company prospects.
  • At a price of $1.28 per share during the withholding, the stock appears to be trading at depressed levels, potentially reflecting biotech sector challenges or company-specific headwinds given CGTX operates in the therapeutics space.
Sentiment: Neutral Significance: 2/10
View Original Filing →
Current Report Filed: 2026-03-26

Key Insights

  • Cognition Therapeutics announced its financial results for the year ended December 31, 2025, indicating the company's performance during the previous fiscal year.
  • The company has provided an investor presentation that may be used in discussions with investors, analysts, and other parties, which could offer additional insights into the company's operations and strategy.
  • Cognition Therapeutics is an emerging growth company, which may provide it with more flexibility in complying with financial reporting standards.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Annual Report Filed: 2026-03-26

Key Insights

  • Cognition Therapeutics raised significant capital through various equity offerings in 2024 and 2025, indicating strong investor interest in the company's therapeutic pipeline.
  • The company's research and development expenses have increased steadily, suggesting active progress in its clinical development programs.
  • Cognition Therapeutics has entered into agreements with institutional investors and an equity line financing, providing additional financial flexibility to support its operations.
Sentiment: Positive Significance: 7/10
View Original Filing →
Current Report Filed: 2026-03-02

Key Insights

  • Cognition Therapeutics plans to advance the development of zervimesine for the treatment of dementia with Lewy bodies psychosis, indicating progress in their pipeline.
  • The company's stock is traded on the Nasdaq stock exchange under the ticker symbol CGTX.
  • Cognition Therapeutics is an emerging growth company, which means it may take advantage of certain exemptions from financial reporting and other requirements.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-02-18

Key Insights

  • The reporting person, Anthony Caggiano, who is the Chief Medical Officer of Cognition Therapeutics Inc., disposed of 4,680 shares of common stock through a share withholding transaction to cover tax obligations.
  • The reporting person still holds a significant direct ownership stake of 864,906 shares in the company, indicating continued alignment with shareholder interests.
  • The transaction was executed at a price of $1.12 per share, which appears to be in line with the current market price.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-02-18

Key Insights

  • The reporting person, John Brendan Doyle, Chief Financial Officer of Cognition Therapeutics Inc., has disposed of 1,560 shares of the company's common stock through a share withholding transaction to cover tax obligations.
  • This transaction reduces Doyle's direct beneficial ownership of Cognition Therapeutics' common stock to 617,509 shares.
  • Insider transactions, such as this share disposal, can provide insights into management's views on the company's valuation and future prospects.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-02-18

Key Insights

  • Lisa Ricciardi, the CEO and President of Cognition Therapeutics, sold 5,850 shares of the company's common stock at $1.12 per share, suggesting potential insider selling activity.
  • Ricciardi still holds a significant stake in the company, with 1,706,676 shares beneficially owned directly and an additional 38,851 shares held indirectly through her spouse.
  • The transaction was made to cover tax withholding obligations in connection with the vesting of restricted stock units, indicating a common practice for executive compensation management.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-02-05

Key Insights

  • Anthony Caggiano, the Chief Medical Officer of Cognition Therapeutics Inc., acquired 400,000 shares of the company's common stock at no cost through restricted stock units (RSUs).
  • Caggiano also disposed of 38,407 shares to cover tax withholding obligations, reducing his direct ownership to 869,586 shares.
  • The timing and amount of Caggiano's RSU acquisition and share dispositions suggest his confidence in the company's future prospects and alignment with shareholder interests.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-02-05

Key Insights

  • John Brendan Doyle, the Chief Financial Officer of Cognition Therapeutics Inc., has acquired 200,000 shares of the company's common stock through restricted stock units (RSUs), increasing his direct ownership to 645,990 shares.
  • Doyle also disposed of 26,921 shares to cover tax withholding obligations, reducing his direct ownership to 619,069 shares.
  • The acquisition of shares through RSUs and the disposition of shares to cover taxes suggest Doyle's continued commitment to the company and alignment with shareholder interests.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-02-05

Key Insights

  • Lisa Ricciardi, the CEO and President of Cognition Therapeutics Inc., acquired 800,000 shares of the company's common stock at no cost, indicating confidence in the company's future prospects.
  • Ricciardi also disposed of 26,036 and 51,704 shares on February 3 and 4, 2026, respectively, likely to cover tax withholding obligations, suggesting a partially cash-funded compensation structure.
  • The company's insider ownership increased, with Ricciardi's spouse holding an additional 38,851 shares, potentially aligning the leadership's interests with those of shareholders.
Sentiment: Positive Significance: 7/10
View Original Filing →
Current Report Filed: 2026-01-27

Key Insights

  • Cognition Therapeutics announced the completion of a Tye C meeting with the FDA for its dementia with Lewy bodies drug candidate zervimesine, indicating progress in the regulatory process.
  • The company is an emerging growth pharmaceutical firm, which may mean it has greater flexibility in financial reporting and accounting standards compared to more established firms.
  • No other material events or changes were reported in the 8-K filing, suggesting the company's operations and leadership are stable at this time.
Sentiment: Positive Significance: 6/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.